Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: GPR55 is a G protein-coupled receptor that is weakly activated by some cannabinoids (CBs) at nM concentrations but displays a 5- to 10-fold greater stimulation in response to 1 µM lysophosphatidylinositol (LPI). ML-184 is a potent synthetic agonist of GPR55 (EC50 = 0.26 µM). It does not act at the related kynurenic acid receptor GPR35 and is a weak antagonist of CB1 and CB2 (IC50s = 21.8 and 15.1 µM, respectively). Like LPI, ML-184 induces phosphorylation of ERK1/2 and translocation of PKC beta II to the plasma membrane by activating GPR55.
ML-184 is supplied as a crystalline solid. A stock solution may be made by dissolving the ML-184 in the solvent of choice. ML-184 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ML-184 in these solvents is approximately 1, 20, and 30 mg/ml. ML-184 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ML-184 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. ML-184 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Ryberg, E., Larsson, N., Sjögren, S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101 (2007).
Oka, S., Nakajima, K., Yamashita, A., et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934 (2007).
Kotsikorou, E., Madrigal, K.E., Hurst, D.P., et al. Identification of the GPR55 agonist binding site using a novel set of high potency GPR55 selective ligands. Biochemistry 50(25), 5633-5647 (2011).